| 1 | Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network | 1.0 | 2 | Citations (PDF) |
| 2 | Choice of Frontline Tyrosine‐Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A “Campus CML” Study | 1.8 | 2 | Citations (PDF) |
| 3 | The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real‐world study on AIFA monitoring registries | 2.7 | 15 | Citations (PDF) |
| 4 | Clinical and biological advances of critical complications in acute myeloid leukemia | 1.4 | 4 | Citations (PDF) |
| 5 | Chronic eosinophilic leukaemia—Not otherwise specified: Clinical features, genomic insight and therapeutic strategies | 2.7 | 3 | Citations (PDF) |
| 6 | Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML) | 2.0 | 9 | Citations (PDF) |
| 7 | Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib | 2.6 | 1 | Citations (PDF) |
| 8 | SOHO State of the Art Updates and Next Questions: Combination Therapy in Chronic Myeloid Leukemia in Chronic Phase | 1.0 | 1 | Citations (PDF) |
| 9 | Asciminib in the treatment of chronic myeloid leukemia in chronic phase | 2.3 | 6 | Citations (PDF) |
| 10 | SOHO State of the Art Updates and Next Questions | Atypical Chronic Myeloid Leukemia: Pathogenesis, Diagnostic Challenges and Therapeutic Strategies | 1.0 | 1 | Citations (PDF) |
| 11 | Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI) | 4.0 | 11 | Citations (PDF) |
| 12 | Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies | 2.9 | 2 | Citations (PDF) |
| 13 | Extracellular vesicles as source of biomarkers in hematological malignancies: looking towards clinical applications | 3.0 | 2 | Citations (PDF) |
| 14 | Baseline, Drug‐Related and Persistent Anemia and/or Thrombocytopenia Predict Responses and Prognosis in Myelofibrosis Patients Treated With Ruxolitinib | 2.1 | 3 | Citations (PDF) |
| 15 | CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITD
<sup>mut</sup>
-AML): a flow-cytometric marker for an accurate diagnostic workup | 1.4 | 0 | Citations (PDF) |
| 16 | Real‐World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi‐Resistant Chronic‐Phase Chronic Myeloid Leukemia (CML‐CP) Patient Population | 2.1 | 5 | Citations (PDF) |
| 17 | Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea | 7.7 | 7 | Citations (PDF) |
| 18 | Chronic myeloid leukemia outcomes according to baseline risk and first‐line treatment in real‐world settings: Data from the Italian Network/CML Campus | 4.0 | 1 | Citations (PDF) |
| 19 | Management of chronic myeloid leukemia in 2025 | 4.0 | 38 | Citations (PDF) |
| 20 | Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study | 2.1 | 0 | Citations (PDF) |
| 21 | Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib | 4.0 | 6 | Citations (PDF) |
| 22 | Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia | 4.0 | 16 | Citations (PDF) |
| 23 | Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort | 1.8 | 0 | Citations (PDF) |
| 24 | Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort | 6.5 | 46 | Citations (PDF) |
| 25 | How to improve treatment‐free remission eligibility in chronic myeloid leukaemia? | 2.7 | 11 | Citations (PDF) |
| 26 | Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy | 4.0 | 18 | Citations (PDF) |
| 27 | Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia | 2.5 | 10 | Citations (PDF) |
| 28 | Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report | 2.6 | 1 | Citations (PDF) |
| 29 | e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response | 2.5 | 4 | Citations (PDF) |
| 30 | Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation | 1.8 | 6 | Citations (PDF) |
| 31 | Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors | 2.1 | 8 | Citations (PDF) |
| 32 | First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosisBlood, 2024, 143, 1399-1413 | 4.8 | 10 | Citations (PDF) |
| 33 | Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results | 7.7 | 51 | Citations (PDF) |
| 34 | Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety | 2.6 | 8 | Citations (PDF) |
| 35 | Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real‐world case series | 2.7 | 5 | Citations (PDF) |
| 36 | Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives | 2.6 | 13 | Citations (PDF) |
| 37 | Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study | 4.0 | 12 | Citations (PDF) |
| 38 | Shedding light on resistance to asciminibBlood, 2024, 144, 594-595 | 4.8 | 6 | Citations (PDF) |
| 39 | Real-Life Management of FLT3-Mutated AML: Single-Centre Experience over 24 Years | 3.8 | 5 | Citations (PDF) |
| 40 | Leucocytosis during induction therapy with all‐trans‐retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment‐related complications | 2.7 | 14 | Citations (PDF) |
| 41 | Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia | 3.8 | 3 | Citations (PDF) |
| 42 | Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time | 1.5 | 4 | Citations (PDF) |
| 43 | Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison | 2.6 | 7 | Citations (PDF) |
| 44 | Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases | 2.1 | 3 | Citations (PDF) |
| 45 | Management of polycythemia vera: A survey of treatment patterns in Italy | 1.8 | 3 | Citations (PDF) |
| 46 | Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome | 4.0 | 41 | Citations (PDF) |
| 47 | Management of Chronic Myeloid Leukemia Patients in Later Lines: The Role of Ponatinib and New Compounds | 1.0 | 6 | Citations (PDF) |
| 48 | Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results | 7.7 | 51 | Citations (PDF) |
| 49 | Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA) | 1.5 | 3 | Citations (PDF) |
| 50 | Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials | 1.5 | 8 | Citations (PDF) |
| 51 | Case Report: Infectious prophylaxis in hematological malignancies | 2.6 | 5 | Citations (PDF) |
| 52 | Systemic mastocytosis: 2023 update on diagnosis and management in adults | 2.3 | 12 | Citations (PDF) |
| 53 | Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination | 2.6 | 3 | Citations (PDF) |
| 54 | Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic‐phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML | 4.0 | 7 | Citations (PDF) |
| 55 | Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib | 5.5 | 0 | Citations (PDF) |
| 56 | CCND2
mutations in atypical chronic myeloid leukemia: a report of two cases | 1.4 | 5 | Citations (PDF) |
| 57 | Myelodysplastic clones arising post chimeric antigen receptor t cell therapy (car-t) procedure: a casuality or a new entity? | 1.5 | 0 | Citations (PDF) |
| 58 | Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study | 3.8 | 15 | Citations (PDF) |
| 59 | One‐month qRT‐PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission | 1.8 | 2 | Citations (PDF) |
| 60 | A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis | 3.8 | 8 | Citations (PDF) |
| 61 | Atypical CML: diagnosis and treatment | 2.7 | 9 | Citations (PDF) |
| 62 | A traffic light for TFR by lineage-specific MRDBlood, 2023, 142, 2129-2130 | 4.8 | 1 | Citations (PDF) |
| 63 | Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI) | 1.4 | 9 | Citations (PDF) |
| 64 | COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report | 2.7 | 22 | Citations (PDF) |
| 65 | Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients | 2.2 | 5 | Citations (PDF) |
| 66 | Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX‐IOL study | 2.7 | 13 | Citations (PDF) |
| 67 | Physicians’ Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform | 2.6 | 11 | Citations (PDF) |
| 68 | Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study | 2.6 | 15 | Citations (PDF) |
| 69 | Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group | 1.5 | 3 | Citations (PDF) |
| 70 | Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic‐phase myelofibrosis | 4.0 | 14 | Citations (PDF) |
| 71 | Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients | 2.0 | 6 | Citations (PDF) |
| 72 | Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity? | 2.5 | 2 | Citations (PDF) |
| 73 | Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges | 1.5 | 7 | Citations (PDF) |
| 74 | Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy | 2.5 | 13 | Citations (PDF) |
| 75 | Future Management of Chronic Myeloid Leukemia: From Dose Optimization
to New Agents | 3.1 | 1 | Citations (PDF) |
| 76 | Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group | 1.4 | 0 | Citations (PDF) |
| 77 | PB1902: ASC4OPT TRIAL IN PROGRESS: A PHASE 3B OPEN-LABEL OPTIMIZATION STUDY OF ORAL ASCIMINIB IN CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE PREVIOUSLY TREATED WITH 2 OR MORE TYROSINE KINASE INHIBITORS | 0.4 | 1 | Citations (PDF) |
| 78 | Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia | 8.5 | 11 | Citations (PDF) |
| 79 | Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance | 3.0 | 4 | Citations (PDF) |
| 80 | A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase | 24.1 | 49 | Citations (PDF) |
| 81 | Management of chronic myeloid leukaemia patients treated with ponatinib in a real‐life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA) | 2.7 | 17 | Citations (PDF) |
| 82 | Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine | 7.7 | 4 | Citations (PDF) |
| 83 | Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors | 2.1 | 0 | Citations (PDF) |
| 84 | Asciminib as a third line option in chronic myeloid leukemia | 1.5 | 9 | Citations (PDF) |
| 85 | Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide | 5.5 | 16 | Citations (PDF) |
| 86 | Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation | 2.5 | 8 | Citations (PDF) |
| 87 | CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions | 2.8 | 7 | Citations (PDF) |
| 88 | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience | 3.8 | 7 | Citations (PDF) |
| 89 | From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care | 2.0 | 1 | Citations (PDF) |
| 90 | The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy | 3.3 | 9 | Citations (PDF) |
| 91 | Therapeutic strategies in low and high-risk MDS: What does the future have to offer? | 5.1 | 33 | Citations (PDF) |
| 92 | Very late acute myeloid leukemia relapse: clinical features, treatment and outcome | 1.4 | 4 | Citations (PDF) |
| 93 | Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort | 1.0 | 2 | Citations (PDF) |
| 94 | Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia | 1.4 | 23 | Citations (PDF) |
| 95 | Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study | 1.4 | 4 | Citations (PDF) |
| 96 | Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice? | 5.0 | 15 | Citations (PDF) |
| 97 | Second primary malignancy in myelofibrosis patients treated with ruxolitinib | 2.7 | 36 | Citations (PDF) |
| 98 | Early Palliative Home Care versus Hospital Care for Patients with Hematologic Malignancies: A Cost-Effectiveness Study | 1.3 | 22 | Citations (PDF) |
| 99 | Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up | 1.4 | 4 | Citations (PDF) |
| 100 | Outcomes of long‐term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis | 3.0 | 9 | Citations (PDF) |
| 101 | Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis | 5.5 | 71 | Citations (PDF) |
| 102 | Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge | 2.5 | 36 | Citations (PDF) |
| 103 | Impact of comorbidities and body mass index on the outcome of polycythemia vera patients | 2.1 | 23 | Citations (PDF) |
| 104 | Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors | 2.0 | 12 | Citations (PDF) |
| 105 | Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia | 2.6 | 8 | Citations (PDF) |
| 106 | Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience | 1.4 | 1 | Citations (PDF) |
| 107 | Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors | 2.1 | 15 | Citations (PDF) |
| 108 | Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients | 1.5 | 7 | Citations (PDF) |
| 109 | Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase | 2.6 | 16 | Citations (PDF) |
| 110 | New dead/H-box helicase gene (ddx41) mutation in an Italian family with recurrent leukemia | 1.4 | 6 | Citations (PDF) |
| 111 | Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome | 4.0 | 24 | Citations (PDF) |
| 112 | Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study | 7.7 | 6 | Citations (PDF) |
| 113 | Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy | 2.6 | 1 | Citations (PDF) |
| 114 | Measuring prognosis in chronic myeloid leukemia: what’s new? | 2.0 | 4 | Citations (PDF) |
| 115 | Health-related quality of life in patients with acute promyelocytic leukemia: a systematic literature review | 2.0 | 2 | Citations (PDF) |
| 116 | Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network | 2.6 | 16 | Citations (PDF) |
| 117 | Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols | 1.8 | 7 | Citations (PDF) |
| 118 | Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios | 3.8 | 9 | Citations (PDF) |
| 119 | The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L | 3.7 | 34 | Citations (PDF) |
| 120 | Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy | 5.0 | 16 | Citations (PDF) |
| 121 | Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study | 1.8 | 9 | Citations (PDF) |
| 122 | Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA) | 1.5 | 18 | Citations (PDF) |
| 123 | Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib | 1.5 | 17 | Citations (PDF) |
| 124 | Hemorrhagic Complications in Patients Treated With Azacitidine and Direct Oral Anticoagulants | 0.5 | 2 | Citations (PDF) |
| 125 | Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors | 2.2 | 25 | Citations (PDF) |
| 126 | Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis | 4.0 | 149 | Citations (PDF) |
| 127 | The role of cladribine in acute myeloid leukemia: an old drug up to new tricks | 1.4 | 11 | Citations (PDF) |
| 128 | Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment | 2.1 | 8 | Citations (PDF) |
| 129 | How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey | 7.7 | 18 | Citations (PDF) |
| 130 | A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation | 2.5 | 4 | Citations (PDF) |
| 131 | Favorable outcome of chronic myeloid leukemia co‐expressing e13a2 and e14a2 transcripts, treated with nilotinib | 2.1 | 2 | Citations (PDF) |
| 132 | Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors | 2.1 | 10 | Citations (PDF) |
| 133 | Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance | 1.4 | 2 | Citations (PDF) |
| 134 | On the road to treatment-free remission in chronic myeloid leukemia: what about ‘the others’? | 2.5 | 6 | Citations (PDF) |
| 135 | COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey | 7.7 | 18 | Citations (PDF) |
| 136 | Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab | 1.5 | 7 | Citations (PDF) |
| 137 | Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience | 1.5 | 12 | Citations (PDF) |
| 138 | Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice | 2.0 | 9 | Citations (PDF) |
| 139 | Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia | 1.8 | 4 | Citations (PDF) |
| 140 | Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors | 7.7 | 102 | Citations (PDF) |
| 141 | Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients | 1.5 | 10 | Citations (PDF) |
| 142 | Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors | 1.5 | 10 | Citations (PDF) |
| 143 | Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study | 5.5 | 8 | Citations (PDF) |
| 144 | Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia | 2.6 | 25 | Citations (PDF) |
| 145 | Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey | 7.7 | 58 | Citations (PDF) |
| 146 | High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity | 1.5 | 3 | Citations (PDF) |
| 147 | Direct oral anticoagulants in patients with hematologic malignancies | 2.1 | 13 | Citations (PDF) |
| 148 | The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index | 7.7 | 18 | Citations (PDF) |
| 149 | Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data | 2.1 | 23 | Citations (PDF) |
| 150 | Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force | 1.8 | 13 | Citations (PDF) |
| 151 | How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA) | 2.6 | 42 | Citations (PDF) |
| 152 | Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the “Ph1‐negative Myeloproliferative Neoplasms Latium Group” | 1.8 | 13 | Citations (PDF) |
| 153 | Prognostic Significance of Transcript-Type BCR‐ABL1 in Chronic Myeloid Leukemia | 4.5 | 23 | Citations (PDF) |
| 154 | Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline | 1.5 | 19 | Citations (PDF) |
| 155 | Maintenance therapy in AML: The past, the present and the future | 6.5 | 91 | Citations (PDF) |
| 156 | Digital droplet PCR at the time of TKI discontinuation in chronic‐phase chronic myeloid leukemia patients is predictive of treatment‐free remission outcome | 2.1 | 23 | Citations (PDF) |
| 157 | A journey through infectious risk associated with ruxolitinib | 2.7 | 35 | Citations (PDF) |
| 158 | Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis | 1.5 | 5 | Citations (PDF) |
| 159 | Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice | 1.5 | 10 | Citations (PDF) |
| 160 | Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative | 6.5 | 6 | Citations (PDF) |
| 161 | Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life | 1.5 | 11 | Citations (PDF) |
| 162 | Treatment of Philadelphia‐negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors | 2.1 | 16 | Citations (PDF) |
| 163 | Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice | 1.5 | 10 | Citations (PDF) |
| 164 | Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention | 2.2 | 20 | Citations (PDF) |
| 165 | Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib | 2.1 | 5 | Citations (PDF) |
| 166 | Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart | 2.1 | 69 | Citations (PDF) |
| 167 | Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia | 2.9 | 36 | Citations (PDF) |
| 168 | Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP | 5.0 | 80 | Citations (PDF) |
| 169 | Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology☆ | 1.9 | 13 | Citations (PDF) |
| 170 | Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper | 24.1 | 65 | Citations (PDF) |
| 171 | Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure | 34.5 | 435 | Citations (PDF) |
| 172 | Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter? | 0.7 | 9 | Citations (PDF) |
| 173 | Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia | 2.0 | 15 | Citations (PDF) |
| 174 | The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review | 2.3 | 28 | Citations (PDF) |
| 175 | Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial | 7.7 | 59 | Citations (PDF) |
| 176 | Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy | 7.7 | 44 | Citations (PDF) |
| 177 | Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice | 1.5 | 15 | Citations (PDF) |
| 178 | PS1172 DDPCR AT THE TIME OF TKI DISCONTINUATION IN CHRONIC PHASE CHRONIC MYELOID PATIENTS IS PREDICTIVE OF TREATMENT‐FREE REMISSION OUTCOME | 0.4 | 0 | Citations (PDF) |
| 179 | Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia | 4.2 | 21 | Citations (PDF) |
| 180 | Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment | 1.5 | 12 | Citations (PDF) |
| 181 | Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian ‘Back to Life’ project | 2.1 | 18 | Citations (PDF) |
| 182 | Health‐related quality of life in patients with chronic myeloid leukemia receiving first‐line therapy with nilotinib | 4.0 | 28 | Citations (PDF) |
| 183 | Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice | 1.5 | 37 | Citations (PDF) |
| 184 | Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients | 2.1 | 56 | Citations (PDF) |
| 185 | Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up | 0.7 | 2 | Citations (PDF) |
| 186 | Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option | 2.1 | 21 | Citations (PDF) |
| 187 | Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy | 2.0 | 9 | Citations (PDF) |
| 188 | Comparison of JAK2V617F‐positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology | 2.1 | 13 | Citations (PDF) |
| 189 | Efficacy and safety of ruxolitinib in intermediate‐1 IPSS risk myelofibrosis patients: Results from an independent study | 2.1 | 44 | Citations (PDF) |
| 190 | Association between proteomic profile and molecular response in chronic myeloid leukemia patients | 1.4 | 1 | Citations (PDF) |
| 191 | Patient‐reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes | 4.0 | 38 | Citations (PDF) |
| 192 | Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events | 1.5 | 21 | Citations (PDF) |
| 193 | Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib | 2.6 | 15 | Citations (PDF) |
| 194 | Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy | 1.5 | 23 | Citations (PDF) |
| 195 | Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission | 2.6 | 103 | Citations (PDF) |
| 196 | Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients | 2.7 | 10 | Citations (PDF) |
| 197 | Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ | 3.1 | 32 | Citations (PDF) |
| 198 | Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse? | 1.8 | 5 | Citations (PDF) |
| 199 | Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia | 1.5 | 16 | Citations (PDF) |
| 200 | Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia | 7.7 | 21 | Citations (PDF) |
| 201 | Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib | 1.5 | 16 | Citations (PDF) |
| 202 | Ponatinib: A Review of Efficacy and Safety | 3.1 | 76 | Citations (PDF) |
| 203 | Impact of exclusion criteria for the DASISION and ENESTnd trials in the front‐line treatment of a ‘real‐life’ patient population with chronic myeloid leukaemia | 2.1 | 13 | Citations (PDF) |
| 204 | Iron‐chelating therapy with deferasirox in transfusion‐dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study | 2.7 | 25 | Citations (PDF) |
| 205 | The BCR‐ABL1 transcript type influences response and outcome inPhiladelphia chromosome‐positive chronic myeloid leukemia patients treated frontline with imatinib | 6.5 | 87 | Citations (PDF) |
| 206 | Second line small molecule therapy options for treating chronic myeloid leukemia | 2.1 | 9 | Citations (PDF) |
| 207 | Are chronic myeloid leukemia patients ready to stop long-term treatment? | 1.4 | 2 | Citations (PDF) |
| 208 | Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia | 2.6 | 10 | Citations (PDF) |
| 209 | A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts | 7.7 | 69 | Citations (PDF) |
| 210 | How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes | 2.0 | 9 | Citations (PDF) |
| 211 | Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real‐life | 6.5 | 8 | Citations (PDF) |
| 212 | Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update | 3.0 | 15 | Citations (PDF) |
| 213 | The Eutos long‐term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials | 6.5 | 17 | Citations (PDF) |
| 214 | High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia | 2.3 | 12 | Citations (PDF) |
| 215 | Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients | 6.5 | 87 | Citations (PDF) |
| 216 | Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia | 2.1 | 8 | Citations (PDF) |
| 217 | Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients | 2.9 | 0 | Citations (PDF) |
| 218 | Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series | 1.5 | 37 | Citations (PDF) |
| 219 | Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase | 1.8 | 20 | Citations (PDF) |
| 220 | Rotation of nilotinib and imatinib for first‐line treatment of chronic phase chronic myeloid leukemia | 6.5 | 11 | Citations (PDF) |
| 221 | Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real‐world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia | 1.8 | 33 | Citations (PDF) |
| 222 | Current First- and Second-Line Treatment Options in Acute Promyelocytic Leukemia | 2.4 | 5 | Citations (PDF) |
| 223 | European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia | 7.7 | 447 | Citations (PDF) |
| 224 | PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy | 7.7 | 82 | Citations (PDF) |
| 225 | Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study | 1.5 | 8 | Citations (PDF) |
| 226 | Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia | 7.0 | 26 | Citations (PDF) |
| 227 | Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies | 2.2 | 25 | Citations (PDF) |
| 228 | Early molecular response in chronic myeloid leukemia and halving time: Latest evidences | 0.7 | 14 | Citations (PDF) |
| 229 | Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline | 5.0 | 15 | Citations (PDF) |
| 230 | Current standard treatment of adult acute promyelocytic leukaemia | 2.7 | 70 | Citations (PDF) |
| 231 | Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis | 2.2 | 13 | Citations (PDF) |
| 232 | How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety | 2.1 | 2 | Citations (PDF) |
| 233 | Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients | 6.5 | 37 | Citations (PDF) |
| 234 | Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia | 2.6 | 12 | Citations (PDF) |
| 235 | Do the smoking intensity and duration, the years since quitting, the methodological quality and the year of publication of the studies affect the results of the meta-analysis on cigarette smoking and Acute Myeloid Leukemia (AML) in adults? | 5.0 | 25 | Citations (PDF) |
| 236 | Dasatinib first-line: Multicentric Italian experience outside clinical trials | 0.7 | 6 | Citations (PDF) |
| 237 | Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion | 1.5 | 52 | Citations (PDF) |
| 238 | Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN | 1.5 | 16 | Citations (PDF) |
| 239 | Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with MyelofibrosisBlood, 2016, 128, 1128-1128 | 4.8 | 4 | Citations (PDF) |
| 240 | Incidence of Early Thrombosis in Myeloproliferative Neoplasms (MPN): A Prospective Analysis from the Gruppo Laziale of Ph-Negative MPNBlood, 2016, 128, 1951-1951 | 4.8 | 4 | Citations (PDF) |
| 241 | Health Related Quality of Life of Long-Term Survivors of Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and ChemotherapyBlood, 2016, 128, 2415-2415 | 4.8 | 3 | Citations (PDF) |
| 242 | Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with MyelofibrosisBlood, 2016, 128, 4251-4251 | 4.8 | 2 | Citations (PDF) |
| 243 | Obesity As a Risk Factor for Acute Promyelocytic Leukemia. Results from Population and Case-Control Studies Across Western Countries and Correlation with Gene Expression in the TCGABlood, 2016, 128, 448-448 | 4.8 | 3 | Citations (PDF) |
| 244 | Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI TherapyBlood, 2016, 128, 625-625 | 4.8 | 25 | Citations (PDF) |
| 245 | Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors TherapyBlood, 2016, 128, 942-942 | 4.8 | 2 | Citations (PDF) |
| 246 | Physicians' Attitude Towards Selection of Second Line Therapy with Nilotinib and Dasatinib in Chronic Myeloid Leukemia PatientsBlood, 2016, 128, 5939-5939 | 4.8 | 0 | Citations (PDF) |
| 247 | Inclusion of Patient's Self-Reported Fatigue into a Standard Laboratory Risk Classification Enhances Survival Prediction in Patients with Advanced Myelodysplastic SyndromesBlood, 2016, 128, 1242-1242 | 4.8 | 0 | Citations (PDF) |
| 248 | Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective AnalysisBlood, 2016, 128, 5464-5464 | 4.8 | 0 | Citations (PDF) |
| 249 | Latium (Italy) Epidemiology of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs) from 2011 to 2015: A Prospective Analysis from Gruppo Laziale of Ph Negative MPNBlood, 2016, 128, 5473-5473 | 4.8 | 0 | Citations (PDF) |
| 250 | Essential Thrombocythemia: A Comparison of Overall and Thrombosis Free Survival in Two Discrete Periods of the First Decade of 2000. a Retrospective AnalysisBlood, 2016, 128, 5469-5469 | 4.8 | 0 | Citations (PDF) |
| 251 | Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN)Blood, 2016, 128, 5465-5465 | 4.8 | 1 | Citations (PDF) |
| 252 | Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib | 6.5 | 12 | Citations (PDF) |
| 253 | Updated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia | 0.3 | 2 | Citations (PDF) |
| 254 | Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last? | 2.1 | 5 | Citations (PDF) |
| 255 | Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC) | 2.2 | 48 | Citations (PDF) |
| 256 | Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront | 1.4 | 7 | Citations (PDF) |
| 257 | Characteristics and outcome of therapy‐related myeloid neoplasms: Report from the Italian network on secondary leukemias | 6.5 | 114 | Citations (PDF) |
| 258 | Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis | 0.7 | 14 | Citations (PDF) |
| 259 | Differences among young adults, adults and elderly chronic myeloid leukemia patients | 9.9 | 95 | Citations (PDF) |
| 260 | Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome – Emphasis on optimized dosing schedules and new formulations | 0.7 | 19 | Citations (PDF) |
| 261 | An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms | 1.5 | 28 | Citations (PDF) |
| 262 | Deferasirox chelation therapy in patients with transfusion‐dependent MDS: a ‘real‐world’ report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata | 1.8 | 23 | Citations (PDF) |
| 263 | Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet | 7.7 | 75 | Citations (PDF) |
| 264 | Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis | 7.7 | 69 | Citations (PDF) |
| 265 | Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment | 5.5 | 33 | Citations (PDF) |
| 266 | Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib | 7.7 | 91 | Citations (PDF) |
| 267 | Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study | 27.4 | 82 | Citations (PDF) |
| 268 | Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients | 0.7 | 60 | Citations (PDF) |
| 269 | Bosutinib for Chronic Myeloid Leukemia | 0.5 | 8 | Citations (PDF) |
| 270 | Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia | 0.5 | 8 | Citations (PDF) |
| 271 | Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes | 0.7 | 18 | Citations (PDF) |
| 272 | Erythropoietin treatment in patients with myelodysplastic syndromes and type 2 diabetes 促红细胞生成素治疗骨髓增生异常综合征合并2型糖尿病的患者 | 2.9 | 0 | Citations (PDF) |
| 273 | Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes | 2.7 | 68 | Citations (PDF) |
| 274 | The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia | 1.5 | 24 | Citations (PDF) |
| 275 | Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 PatientsBlood, 2015, 126, 1606-1606 | 4.8 | 2 | Citations (PDF) |
| 276 | Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with MyelofibrosisBlood, 2015, 126, 2799-2799 | 4.8 | 8 | Citations (PDF) |
| 277 | Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?Blood, 2015, 126, 4038-4038 | 4.8 | 1 | Citations (PDF) |
| 278 | Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International StudyBlood, 2015, 126, 2099-2099 | 4.8 | 1 | Citations (PDF) |
| 279 | JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on OutcomeBlood, 2015, 126, 1614-1614 | 4.8 | 0 | Citations (PDF) |
| 280 | Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with NilotinibBlood, 2015, 126, 1570-1570 | 4.8 | 0 | Citations (PDF) |
| 281 | The Platelet COUNT at Diagnosis of Essential Thrombocythemia Is a Prognostic Factor for Thrombosis-Free Survival: Retrospective Analysis on 1201 PatientsBlood, 2015, 126, 2815-2815 | 4.8 | 0 | Citations (PDF) |
| 282 | Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 TrialBlood, 2015, 126, 4046-4046 | 4.8 | 0 | Citations (PDF) |
| 283 | Are ET and PV Patients Two Similar Populations As Concern Thrombotic Risk Factors?Blood, 2015, 126, 2811-2811 | 4.8 | 4 | Citations (PDF) |
| 284 | Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative NeoplasmsBlood, 2015, 126, 2821-2821 | 4.8 | 1 | Citations (PDF) |
| 285 | Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib | 1.4 | 1 | Citations (PDF) |
| 286 | Patient-reported outcomes in acute leukemia: a roadmap for future research | 1.8 | 1 | Citations (PDF) |
| 287 | How tyrosine kinase inhibitors impair metabolism and endocrine system function: A systematic updated review | 0.7 | 49 | Citations (PDF) |
| 288 | ATRA + ATO | 2.8 | 7 | Citations (PDF) |
| 289 | Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes | 9.9 | 44 | Citations (PDF) |
| 290 | Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors | 0.7 | 35 | Citations (PDF) |
| 291 | Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: Treatment-free remission as a new goal in chronic myeloid leukemia | 8.6 | 16 | Citations (PDF) |
| 292 | Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study | 1.5 | 9 | Citations (PDF) |
| 293 | Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era | 6.5 | 16 | Citations (PDF) |
| 294 | Thrombosis and survival in essential thrombocythemia: A regional study of 1,144 patients | 6.5 | 38 | Citations (PDF) |
| 295 | Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival | 0.7 | 33 | Citations (PDF) |
| 296 | Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve? | 1.5 | 24 | Citations (PDF) |
| 297 | Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocitic leukemia cells | 1.5 | 24 | Citations (PDF) |
| 298 | Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients | 0.7 | 32 | Citations (PDF) |
| 299 | Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11–12, 2013 | 5.0 | 5 | Citations (PDF) |
| 300 | Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age | 1.5 | 15 | Citations (PDF) |
| 301 | Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment | 1.5 | 64 | Citations (PDF) |
| 302 | Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series | 4.8 | 5 | Citations (PDF) |
| 303 | Prognostic Factors for Thrombosis-Free Survival and Overall Survival in Polycytemia Vera: A Retrospective Analysis of 623 Patients Series with Long Follow-upBlood, 2014, 124, 1855-1855 | 4.8 | 0 | Citations (PDF) |
| 304 | Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working PartyBlood, 2014, 124, 4532-4532 | 4.8 | 0 | Citations (PDF) |
| 305 | “Real-life” Frontline Dasatinib Treatment in Unselected Elderly Patients with Chronic Myeloid LeukemiaBlood, 2014, 124, 5530-5530 | 4.8 | 0 | Citations (PDF) |
| 306 | Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid LeukemiaBlood, 2014, 124, 3687-3687 | 4.8 | 0 | Citations (PDF) |
| 307 | Systematic Coronary Risk Evaluation (SCORE) Chart Identify Chronic Myeloid Leukemia Patients at Risk of Cardiovascular Diseases during Nilotinib TreatmentBlood, 2014, 124, 4545-4545 | 4.8 | 0 | Citations (PDF) |
| 308 | Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS RegistryBlood, 2014, 124, 3265-3265 | 4.8 | 0 | Citations (PDF) |
| 309 | Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid LeukemiaBlood, 2014, 124, 1063-1063 | 4.8 | 0 | Citations (PDF) |
| 310 | Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic AspectsBlood, 2014, 124, 5326-5326 | 4.8 | 0 | Citations (PDF) |
| 311 | Hematological Improvement during Deferasirox Treatment in Patients with Myeloproliferative Neoplasms (MPN)Blood, 2014, 124, 3189-3189 | 4.8 | 0 | Citations (PDF) |
| 312 | Analisi costo-efficacia di dasatinib nella prospettiva del SSN italiano | 0.1 | 0 | Citations (PDF) |
| 313 | Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia | 2.1 | 60 | Citations (PDF) |
| 314 | Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia | 34.5 | 1,528 | Citations (PDF) |
| 315 | Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study | 3.2 | 41 | Citations (PDF) |
| 316 | Management Options for Refractory Chronic Myeloid Leukemia: Considerations for the Elderly | 3.2 | 3 | Citations (PDF) |
| 317 | Imatinib induces body mass changes in women with chronic myeloid leukemia | 1.5 | 5 | Citations (PDF) |
| 318 | Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation | 1.5 | 3 | Citations (PDF) |
| 319 | Efficacy and safety of deferasirox in myelodysplastic syndromes | 1.5 | 29 | Citations (PDF) |
| 320 | Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine | 1.4 | 8 | Citations (PDF) |
| 321 | Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy | 1.4 | 30 | Citations (PDF) |
| 322 | Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib | 8.6 | 22 | Citations (PDF) |
| 323 | Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors | 0.7 | 38 | Citations (PDF) |
| 324 | Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher‐risk myelodysplastic syndromes or chronic myelomonocytic leukemia | 1.8 | 40 | Citations (PDF) |
| 325 | Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols | 0.7 | 3 | Citations (PDF) |
| 326 | The limit for chronic myeloid leukemia relapse after allogeneic hematopoietic stem cell transplant moves ever forward: when can you safely talk about healing? | 1.4 | 1 | Citations (PDF) |
| 327 | High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study | 1.4 | 55 | Citations (PDF) |
| 328 | Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization | 1.4 | 5 | Citations (PDF) |
| 329 | Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib | 7.7 | 136 | Citations (PDF) |
| 330 | Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemiaBlood, 2013, 121, 5138-5144 | 4.8 | 55 | Citations (PDF) |
| 331 | Systematic review of dasatinib in chronic myeloid leukemia | 2.7 | 14 | Citations (PDF) |
| 332 | Validation of a new proposed relapse risk score (CBC-score) for acute promyelocytic leukaemia | 1.5 | 1 | Citations (PDF) |
| 333 | Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML) | 6.2 | 30 | Citations (PDF) |
| 334 | International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24 | 2.1 | 75 | Citations (PDF) |
| 335 | Arsenic Trioxide-Based Therapy Of Relapsed Acute Promyelocytic Leukemia: Updated Results Of The European Registry Of Relapsed APL (PROMYSE)Blood, 2013, 122, 1406-1406 | 4.8 | 2 | Citations (PDF) |
| 336 | Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working PartyBlood, 2013, 122, 258-258 | 4.8 | 2 | Citations (PDF) |
| 337 | Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a “Real-life” Patient Population With Chronic Myelogenous Leukemia?Blood, 2013, 122, 4002-4002 | 4.8 | 1 | Citations (PDF) |
| 338 | Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and ChemotherapyBlood, 2013, 122, 770-770 | 4.8 | 2 | Citations (PDF) |
| 339 | 4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working PartyBlood, 2013, 122, 4000-4000 | 4.8 | 0 | Citations (PDF) |
| 340 | FLT3-ITD Internal Tandem Duplication Confers Poor Prognosis In Patients With Acute Promyelocytic Leukemia Treated With The AIDA Protocols. Long-Term Follow-Up AnalysisBlood, 2013, 122, 1336-1336 | 4.8 | 0 | Citations (PDF) |
| 341 | Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary LeukemiasBlood, 2013, 122, 2659-2659 | 4.8 | 0 | Citations (PDF) |
| 342 | Real-Life Efficacy Of Azacitidine In Myelodysplastic Syndromes According To IPSS Cytogenetic ProfileBlood, 2013, 122, 5229-5229 | 4.8 | 0 | Citations (PDF) |
| 343 | Deferasirox In The Treatment Of Iron Overload During Myeloproliferative Neoplasms (MPN)Blood, 2013, 122, 1594-1594 | 4.8 | 0 | Citations (PDF) |
| 344 | Prognostic Factors Associated To Achievement Of Complete Or Partial Response In MDS Patients Treated With Azacitidine Outside Clinical TrialsBlood, 2013, 122, 5203-5203 | 4.8 | 0 | Citations (PDF) |
| 345 | Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients | 6.2 | 22 | Citations (PDF) |
| 346 | 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials | 1.4 | 17 | Citations (PDF) |
| 347 | Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols | 4.8 | 65 | Citations (PDF) |
| 348 | Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response | 1.4 | 20 | Citations (PDF) |
| 349 | Suboptimal response in chronic myeloid leukemia patients treated with imatinib: Early identification and new therapeutic challenges | 8.6 | 1 | Citations (PDF) |
| 350 | Evaluation of prognostic factors for overall survival in patients with chronic myelomonocytic leukemia by different scoring systems: which is the best? | 1.4 | 0 | Citations (PDF) |
| 351 | Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study | 5.5 | 110 | Citations (PDF) |
| 352 | Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? | 1.5 | 56 | Citations (PDF) |
| 353 | How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: Unmet needs, pitfalls and advantages | 8.6 | 14 | Citations (PDF) |
| 354 | Outcome of therapy-related myeloid neoplasms treated with azacitidine | 24.1 | 51 | Citations (PDF) |
| 355 | Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience | 1.4 | 6 | Citations (PDF) |
| 356 | Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease | 2.1 | 48 | Citations (PDF) |
| 357 | Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes | 1.5 | 19 | Citations (PDF) |
| 358 | Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia | 1.4 | 6 | Citations (PDF) |
| 359 | Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population | 1.5 | 32 | Citations (PDF) |
| 360 | Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: A systematic review of efficacy and safety data | 5.0 | 30 | Citations (PDF) |
| 361 | Evaluation of residual CD34+Ph+ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first‐line nilotinib therapy | 4.0 | 14 | Citations (PDF) |
| 362 | Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes | 5.0 | 28 | Citations (PDF) |
| 363 | Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome‐negative myeloproliferative neoplasms | 4.0 | 44 | Citations (PDF) |
| 364 | Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia | 1.5 | 13 | Citations (PDF) |
| 365 | Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study | 1.5 | 23 | Citations (PDF) |
| 366 | Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine | 1.5 | 15 | Citations (PDF) |
| 367 | Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307Blood, 2012, 120, 3784-3784 | 4.8 | 5 | Citations (PDF) |
| 368 | ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG | 4.8 | 18 | Citations (PDF) |
| 369 | The Role of Previous Thrombotic Events in Patients with Essential Thrombocythemia: The Earlier the Worse?Blood, 2012, 120, 5062-5062 | 4.8 | 0 | Citations (PDF) |
| 370 | Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom ExperienceBlood, 2012, 120, 4958-4958 | 4.8 | 0 | Citations (PDF) |
| 371 | Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder PatientsBlood, 2012, 120, 4951-4951 | 4.8 | 0 | Citations (PDF) |
| 372 | Delayed Cytogenetic Response and Reduced Rate of Major Molecular Response Associated to Increased Body Mass Index At Baseline in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib.Blood, 2012, 120, 2784-2784 | 4.8 | 0 | Citations (PDF) |
| 373 | Patient-Reported Fatigue, Functional Aspects and Quality of Life in Elderly Patients with High-Risk Myelodysplastic Syndromes. Evidence From a Large Prospective International Study.Blood, 2012, 120, 3163-3163 | 4.8 | 1 | Citations (PDF) |
| 374 | Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to ImatinibBlood, 2012, 120, 3769-3769 | 4.8 | 0 | Citations (PDF) |
| 375 | Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib TherapyBlood, 2012, 120, 4234-4234 | 4.8 | 0 | Citations (PDF) |
| 376 | Long-Term Follow-up of Chronic Phase Chronic Myeloid Leukemia Patients Who Failed Interferon Alpha and Switched to ImatinibBlood, 2012, 120, 3742-3742 | 4.8 | 0 | Citations (PDF) |
| 377 | Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib.Blood, 2012, 120, 2797-2797 | 4.8 | 2 | Citations (PDF) |
| 378 | Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib | 1.4 | 3 | Citations (PDF) |
| 379 | Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy | 3.0 | 38 | Citations (PDF) |
| 380 | Imatinib treatment in chronic myelogenous leukemia: What have we learned so far? | 8.6 | 35 | Citations (PDF) |
| 381 | Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general populationBlood, 2011, 118, 4554-4560 | 4.8 | 247 | Citations (PDF) |
| 382 | Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working PartyBlood, 2011, 117, 5591-5599 | 4.8 | 106 | Citations (PDF) |
| 383 | Suboptimal response to imatinib according to 2006–2009 European LeukaemiaNet criteria: a ‘grey zone’ at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention | 2.7 | 9 | Citations (PDF) |
| 384 | GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long‐term results and prognostic factors | 2.7 | 22 | Citations (PDF) |
| 385 | 5′-Azacitidine in myelodysplastic syndromes with inversion of chromosome 3 | 7.7 | 6 | Citations (PDF) |
| 386 | Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib | 0.7 | 28 | Citations (PDF) |
| 387 | 5′-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment | 0.7 | 3 | Citations (PDF) |
| 388 | Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second‐generation tyrosine kinase inhibitors | 6.5 | 7 | Citations (PDF) |
| 389 | The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era | 5.0 | 15 | Citations (PDF) |
| 390 | Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients | 0.7 | 36 | Citations (PDF) |
| 391 | Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes | 0.7 | 12 | Citations (PDF) |
| 392 | The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose | 2.1 | 6 | Citations (PDF) |
| 393 | Nilotinib for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia: review of the latest clinical evidence | 0.3 | 2 | Citations (PDF) |
| 394 | Familial occurrence of myelodysplastic syndrome with del(5q) | 1.4 | 0 | Citations (PDF) |
| 395 | Unexpected Erythroid and Cytogenetic Responses After Discontinuation of a Short Course of Lenalidomide As a Result of Severe Skin Rash in a Patient With 5q Syndrome | 16.9 | 6 | Citations (PDF) |
| 396 | Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion | 1.5 | 5 | Citations (PDF) |
| 397 | Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial)Blood, 2011, 118, 2756-2756 | 4.8 | 7 | Citations (PDF) |
| 398 | Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?Blood, 2011, 118, 2770-2770 | 4.8 | 3 | Citations (PDF) |
| 399 | International Development of An EORTC Measure to Assess Patient-Reported Quality of Life (QoL) and Symptoms in Chronic Myeloid Leukemia (CML)Blood, 2011, 118, 3132-3132 | 4.8 | 4 | Citations (PDF) |
| 400 | Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,Blood, 2011, 118, 3783-3783 | 4.8 | 2 | Citations (PDF) |
| 401 | Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working PartyBlood, 2011, 118, 453-453 | 4.8 | 1 | Citations (PDF) |
| 402 | Health-Related Quality of Life Profile and Request of Prognostic Information on Survival At the Time of Diagnosis in Patients with High-Risk Myelodysplastic SyndromesBlood, 2011, 118, 2078-2078 | 4.8 | 1 | Citations (PDF) |
| 403 | Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509Blood, 2011, 118, 786-786 | 4.8 | 5 | Citations (PDF) |
| 404 | Investigating Personal and Treatment Related Factors Associated with Adherence Behavior in Patients with Chronic Myeloid Leukemia Receiving Long Term Imatinib TherapyBlood, 2011, 118, 1026-1026 | 4.8 | 1 | Citations (PDF) |
| 405 | Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib TreatmentBlood, 2011, 118, 4445-4445 | 4.8 | 0 | Citations (PDF) |
| 406 | Clinical Follow-up of Patients with Myeloproliferative Neoplasms Presenting Skin Ulcers During Treatment with HydroxyureaBlood, 2011, 118, 5157-5157 | 4.8 | 0 | Citations (PDF) |
| 407 | Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative PatientsBlood, 2011, 118, 5172-5172 | 4.8 | 0 | Citations (PDF) |
| 408 | Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free SurvivalBlood, 2011, 118, 2751-2751 | 4.8 | 1 | Citations (PDF) |
| 409 | Increased Body Mass Index Correlates with Higher Risk of Disease Relapse and Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia Treated with Aida ProtocolsBlood, 2011, 118, 4866-4866 | 4.8 | 0 | Citations (PDF) |
| 410 | Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose | 2.1 | 14 | Citations (PDF) |
| 411 | Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA GroupBlood, 2010, 116, 3171-3179 | 4.8 | 313 | Citations (PDF) |
| 412 | Changes in RPS14 expression levels during lenalidomide treatment in Low‐ and Intermediate‐1‐risk myelodysplastic syndromes with chromosome 5q deletion | 1.8 | 25 | Citations (PDF) |
| 413 | Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3‐year follow‐up | 6.5 | 11 | Citations (PDF) |
| 414 | Dasatinib, even at low doses, is an effective second‐line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life‐based Italian multicenter retrospective study on 114 patients | 6.5 | 14 | Citations (PDF) |
| 415 | Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib | 0.7 | 38 | Citations (PDF) |
| 416 | Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia | 0.7 | 58 | Citations (PDF) |
| 417 | “Real-life” results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia | 0.7 | 57 | Citations (PDF) |
| 418 | Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients | 1.4 | 17 | Citations (PDF) |
| 419 | Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months | 1.8 | 1 | Citations (PDF) |
| 420 | Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life | 1.4 | 40 | Citations (PDF) |
| 421 | A novel point mutation within the juxtamembrane domain of the flt3 gene in acute myeloid leukemia | 1.5 | 6 | Citations (PDF) |
| 422 | Successful Pregnancy In APL Patients Treated According to the AIDA Protocol.Blood, 2010, 116, 1037-1037 | 4.8 | 2 | Citations (PDF) |
| 423 | Treatment of Molecular and Clinical Relapse of Acute Promyelocytic Leukemia (APL) with Arsenic Trioxide: Results of the European Registry of Relapsed APL | 4.8 | 7 | Citations (PDF) |
| 424 | Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical TrialBlood, 2010, 116, 359-359 | 4.8 | 15 | Citations (PDF) |
| 425 | Comorbidities Indexes In Patients Treated with 5-Azacitidine Are a An Useful and Easily Applicable Tool to Refine Prognostic EvaluationBlood, 2010, 116, 606-606 | 4.8 | 1 | Citations (PDF) |
| 426 | Myelodysplastic Syndrome Patients Younger Than 50 Years: Epidemiological Data and Clinical FeaturesBlood, 2010, 116, 4976-4976 | 4.8 | 0 | Citations (PDF) |
| 427 | First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, “Deep” and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working PartyBlood, 2010, 116, 2720-2720 | 4.8 | 0 | Citations (PDF) |
| 428 | Investigating Preferences and Factors Associated with Involvement In Treatment Decision-Making In Newly Diagnosed Patients with High-Risk Myelodysplastic Syndromes: An International Multicenter StudyBlood, 2010, 116, 4953-4953 | 4.8 | 0 | Citations (PDF) |
| 429 | A Retrospective Epidemiological Analysis of 1572 Cases of Ph1- Myeloprolypherative Neoplasms (MPNs) From 9 Centers In the Latium: Preliminary ResultsBlood, 2010, 116, 5065-5065 | 4.8 | 0 | Citations (PDF) |
| 430 | The Elevated Expression of FBP1, a Key-Enzyme of Gluconeogenesis Gene, Is Associated to High Sokal Risk In Chronic Myeloid Leukemia Patients.Blood, 2010, 116, 3399-3399 | 4.8 | 0 | Citations (PDF) |
| 431 | Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance | 1.4 | 4 | Citations (PDF) |
| 432 | Comorbidities and FLT3‐ITD abnormalities as independent prognostic indicators of survival in Elderly acute myeloid leukaemia patients | 2.1 | 38 | Citations (PDF) |
| 433 | Unusual association of paroxysmal cold hemoglobinuria as the first sign of disease in myelodysplastic patient | 1.5 | 6 | Citations (PDF) |
| 434 | Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results | 1.5 | 2 | Citations (PDF) |
| 435 | Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem? | 2.1 | 6 | Citations (PDF) |
| 436 | Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect? | 2.3 | 8 | Citations (PDF) |
| 437 | Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal | 0.7 | 6 | Citations (PDF) |
| 438 | Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease | 0.7 | 2 | Citations (PDF) |
| 439 | The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism | 0.7 | 23 | Citations (PDF) |
| 440 | Platelet count is an independent prognostic factor in myelodysplastic syndromes considered as low risk by French–American–British and World Health Organisation classifications | 1.4 | 1 | Citations (PDF) |
| 441 | Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience | 1.4 | 61 | Citations (PDF) |
| 442 | Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results | 1.4 | 9 | Citations (PDF) |
| 443 | Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working PartyBlood, 2009, 113, 3428-3434 | 4.8 | 59 | Citations (PDF) |
| 444 | Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemiaBlood, 2009, 114, 4933-4938 | 4.8 | 208 | Citations (PDF) |
| 445 | BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.Blood, 2009, 114, 648-648 | 4.8 | 6 | Citations (PDF) |
| 446 | Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.Blood, 2009, 114, 860-860 | 4.8 | 3 | Citations (PDF) |
| 447 | ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED > 70 Years.Blood, 2009, 114, 4160-4160 | 4.8 | 0 | Citations (PDF) |
| 448 | Acute Erythroid Leukemia: A Distinctive Subtype of AML? Outcome and Prognostic Factors in Comparison with Non-M6 AML. The Gimema Experience.Blood, 2009, 114, 1019-1019 | 4.8 | 0 | Citations (PDF) |
| 449 | Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia: How Important is the Achievement of Complete Cytogenetic Response after 3 Months?Blood, 2009, 114, 4271-4271 | 4.8 | 0 | Citations (PDF) |
| 450 | Clinical Usefulness and Safety of Peripherally-Inserted Central Catethers (PICC) in Hematological Patients.Blood, 2009, 114, 4545-4545 | 4.8 | 0 | Citations (PDF) |
| 451 | Clinical Results in Patients with Primary and Secondary Myelofibrosis Treated with Monthly Cycles of Oral Melphalan.Blood, 2009, 114, 4985-4985 | 4.8 | 0 | Citations (PDF) |
| 452 | Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib | 0.7 | 18 | Citations (PDF) |
| 453 | Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate | 0.7 | 13 | Citations (PDF) |
| 454 | Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma | 0.7 | 9 | Citations (PDF) |
| 455 | Ocular side effects in chronic myeloid leukemia patients treated with imatinib | 0.7 | 52 | Citations (PDF) |
| 456 | Pregnancy in patients with myelodysplastic syndromes (MDS) | 0.7 | 8 | Citations (PDF) |
| 457 | Liposomal daunorubicin versus standard daunorubicin: long term follow‐up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia | 2.7 | 56 | Citations (PDF) |
| 458 | Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients | 1.4 | 8 | Citations (PDF) |
| 459 | Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia | 1.4 | 15 | Citations (PDF) |
| 460 | Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML | 16.9 | 48 | Citations (PDF) |
| 461 | Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: Further evidence for the arbitrary nature of current classification systems | 1.4 | 11 | Citations (PDF) |
| 462 | Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib | 2.7 | 2 | Citations (PDF) |
| 463 | Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose | 2.1 | 3 | Citations (PDF) |
| 464 | High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working PartyBlood, 2008, 112, 181-181 | 4.8 | 19 | Citations (PDF) |
| 465 | Circulating MUC1 Levels (CA15.3) in Myeloproliferative Disorders (MPD)Blood, 2008, 112, 5237-5237 | 4.8 | 2 | Citations (PDF) |
| 466 | Phase II Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM TherapyBlood, 2008, 112, 4288-4288 | 4.8 | 0 | Citations (PDF) |
| 467 | Dasatinib in the Treatment of CML Patients Aged > 60 Years Resistant/Intolerant to ImatinibBlood, 2008, 112, 4253-4253 | 4.8 | 0 | Citations (PDF) |
| 468 | Quality of Life Scores Have a Prognostic Significance In Elderly AML Patients.Blood, 2008, 112, 1949-1949 | 4.8 | 2 | Citations (PDF) |
| 469 | Differences in Haematological and Non Haematological Toxicity during Treatment with Imatinib in Early and Late Chronic Phase Chronic Myeloid Leukemia PatientsBlood, 2008, 112, 4281-4281 | 4.8 | 1 | Citations (PDF) |
| 470 | Prognostic Relevance of Retrospective WHO Re-Classification in 650 MDS Patients Diagnosed by FAB CriteriaBlood, 2008, 112, 5097-5097 | 4.8 | 0 | Citations (PDF) |
| 471 | Comorbidities and FLT3 Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukemia PatientsBlood, 2008, 112, 3983-3983 | 4.8 | 0 | Citations (PDF) |
| 472 | Treatment with Imatinib in Very Elderly (&gt; 75 Years) CML Patients.Blood, 2008, 112, 1096-1096 | 4.8 | 0 | Citations (PDF) |
| 473 | Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: A possible manifestation of retinoic acid syndrome | 1.4 | 2 | Citations (PDF) |
| 474 | Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia | 1.5 | 21 | Citations (PDF) |
| 475 | In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations.Blood, 2007, 110, 1934-1934 | 4.8 | 2 | Citations (PDF) |
| 476 | Improvement of Tolerability and Adverse Events Occurrence during Treatment with Dasatinib Used on a Compassionate Basis in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).Blood, 2007, 110, 4564-4564 | 4.8 | 1 | Citations (PDF) |
| 477 | JAK2 (V617F) Mutation Levels and Marrow Fibrosis in Patients Affected by Budd-Chiari Syndrome and Non-Cirrhotic Extra-Hepatic Portal Vein Obstruction.Blood, 2007, 110, 4652-4652 | 4.8 | 0 | Citations (PDF) |
| 478 | Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Imatinib: Introducing the Concept of Confirmed Molecular Response.Blood, 2007, 110, 1933-1933 | 4.8 | 5 | Citations (PDF) |
| 479 | Changes in Gene Expression Profiles during Treatment with Erythropoetic Growth Factors in Myelodysplastic Syndromes.Blood, 2007, 110, 4609-4609 | 4.8 | 0 | Citations (PDF) |
| 480 | Decisional Flow with a Score System To Start Platelet-Lowering Treatment in Patients with Essential Thrombocythemia (ET): Long-Term Results.Blood, 2007, 110, 4636-4636 | 4.8 | 0 | Citations (PDF) |
| 481 | Role of γ-glutamyl cysteine synthetase (γ-GCS) gene expression as marker of drug sensitivity in acute myeloid leukemias | 1.5 | 11 | Citations (PDF) |
| 482 | Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: focus on DNA repair genes | 7.7 | 35 | Citations (PDF) |
| 483 | Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes | 0.7 | 17 | Citations (PDF) |
| 484 | Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph+ CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon | 0.7 | 31 | Citations (PDF) |
| 485 | Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy | 4.0 | 28 | Citations (PDF) |
| 486 | Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon | 9.9 | 31 | Citations (PDF) |
| 487 | Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features | 7.7 | 115 | Citations (PDF) |
| 488 | Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid | 1.5 | 2 | Citations (PDF) |
| 489 | Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation | 0.7 | 11 | Citations (PDF) |
| 490 | Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment | 0.7 | 20 | Citations (PDF) |
| 491 | Myelodysplastic syndromes in patients under 50 years old: a single institution experience | 0.7 | 23 | Citations (PDF) |
| 492 | BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results | 2.3 | 8 | Citations (PDF) |
| 493 | Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib | 1.8 | 45 | Citations (PDF) |
| 494 | Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib | 1.8 | 68 | Citations (PDF) |
| 495 | Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development? | 1.8 | 9 | Citations (PDF) |
| 496 | Budd-Chiari syndrome as the first manifestation of polycythemia vera in young women with inherited thrombophilic state: an aggressive form of myeloproliferative disorder requiring multidisciplinary management | 1.8 | 12 | Citations (PDF) |
| 497 | Paroxysmal cold haemoglobinuria as a tardive complication of idiopathic myelofibrosis | 1.8 | 9 | Citations (PDF) |
| 498 | Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution | 0.7 | 108 | Citations (PDF) |
| 499 | Imatinib Mesylate May Improve Fasting Blood Glucose in Diabetic Ph+ Chronic Myelogenous Leukemia Patients Responsive to Treatment | 16.9 | 104 | Citations (PDF) |
| 500 | Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemiaBlood, 2004, 104, 1995-1999 | 4.8 | 235 | Citations (PDF) |
| 501 | Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status | 7.7 | 2 | Citations (PDF) |
| 502 | Granulocytic sarcoma of the pancreas successfully treated with intensive chemotherapy and stem cell transplantation | 1.8 | 25 | Citations (PDF) |
| 503 | Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count | 2.7 | 47 | Citations (PDF) |
| 504 | Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen | 7.7 | 42 | Citations (PDF) |
| 505 | Hypermethylation of GpG islands in the promoter region of p15INK4b in acute promyelocytic leukemia represses p15INK4b expression and correlates with poor prognosis | 7.7 | 56 | Citations (PDF) |
| 506 | The importance of molecular monitoring in acute promyelocytic leukaemia | 1.7 | 27 | Citations (PDF) |
| 507 | Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemia | 1.7 | 6 | Citations (PDF) |
| 508 | Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic featuresBlood, 2003, 102, 1035-1041 | 4.8 | 78 | Citations (PDF) |
| 509 | Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia | 7.7 | 18 | Citations (PDF) |
| 510 | Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome | 7.7 | 19 | Citations (PDF) |
| 511 | Ear involvement in acute promyelocytic leukemia at relapse: a disease-associated ‘sanctuary’? | 7.7 | 33 | Citations (PDF) |
| 512 | Therapy-related myelodysplastic syndrome–acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem | 4.8 | 126 | Citations (PDF) |
| 513 | Cutaneous pleomorphic T‐cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine‐containing regimen | 1.8 | 14 | Citations (PDF) |
| 514 | Conservative treatment for patients over 80 years with acute myelogenous leukemia | 6.5 | 13 | Citations (PDF) |
| 515 | Melphalan treatment in patients with myelofibrosis with myeloid metaplasia | 2.7 | 80 | Citations (PDF) |
| 516 | Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission | 2.7 | 26 | Citations (PDF) |
| 517 | Diabetes insipidus as first manifestation of acute myeloid leukaemia with EVI-1-positive, 3q21q26 syndrome and T cell-line antigen expression: what is the EVI-1 gene role? | 2.7 | 23 | Citations (PDF) |
| 518 | Expression pattern of HOXB6 homeobox gene in myelomonocytic differentiation and acute myeloid leukemia | 7.7 | 31 | Citations (PDF) |
| 519 | Ogilvie's syndrome in acute myeloid leukemia: pharmacological approach with neostigmine | 1.5 | 16 | Citations (PDF) |
| 520 | Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission | 2.7 | 16 | Citations (PDF) |
| 521 | Acute Myeloblastic Leukemia Secondary to Myelodysplasia (MDS-AML): A Comparison of Remission Induction with Three Drugs Versus Standard Two-Drugs Induction | 1.4 | 2 | Citations (PDF) |
| 522 | Flt3L induces the ex-vivo
amplification of umbilical cord blood committed progenitors and early stem cells in short-term cultures | 2.7 | 21 | Citations (PDF) |
| 523 | Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy | 7.7 | 17 | Citations (PDF) |
| 524 | The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged >60 years | 9.9 | 25 | Citations (PDF) |
| 525 | Estrogen and progesterone receptors in benign breast tumors and lesions: Relationship with histological and cytological features | 4.3 | 33 | Citations (PDF) |
| 526 | Asciminib: an investigational agent for the treatment of chronic myeloid leukemia | 3.9 | 24 | Citations (PDF) |
| 527 | Title is missing! 0 | | 1 | Citations (PDF) |
| 528 | Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice | 1.4 | 3 | Citations (PDF) |
| 529 | Anemia and blood transfusions in myelofibrosis: economic and organizational impact on Italian patients, caregivers and hospitals | 2.6 | 5 | Citations (PDF) |
| 530 | Treatment Free Remission (TFR) in Chronic Phase‐Chronic Myeloid Leukemia (CP‐CML): Analysis of Predictive Factors and Novel Baseline Scoring System to Predict Molecular Relapse | 1.8 | 5 | Citations (PDF) |
| 531 | Recommendations for best management of polycythemia vera in Italy: a Delphi consensus statement | 1.4 | 0 | Citations (PDF) |
| 532 | Clinical Relevance and Prognostic Value of the Triple A (
<scp>AAA</scp>
) Score in Patients With Myelofibrosis (
<scp>MF</scp>
) Treated With Ruxolitinib (
<scp>RUX</scp>
) | 1.8 | 0 | Citations (PDF) |
| 533 | Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries | 1.5 | 1 | Citations (PDF) |
| 534 | Real World Study on the Best
CPX
‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation | 6.5 | 5 | Citations (PDF) |
| 535 | Increased Rate of Anemia and Discontinuation in Older Patients with Myelofibrosis Treated with Ruxolitinib | 2.5 | 0 | Citations (PDF) |
| 536 | SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia—How to Define the Treatment Value? | 1.0 | 1 | Citations (PDF) |
| 537 | Challenges in the Evolving Role of Calreticulin as a Promising Target for Precision Medicine in Myeloproliferative Neoplasms | 3.8 | 0 | Citations (PDF) |
| 538 | Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint | 7.7 | 2 | Citations (PDF) |
| 539 | Early predictive factors of molecular relapse in chronic phase-chronic myeloid leukemia (CP-CML) patients after tyrosine kinase inhibitor (TKI) discontinuation | 1.4 | 1 | Citations (PDF) |
| 540 | A novel complex mutation affecting two codons in the exon 10 hotspot region of the MPL gene | 1.7 | 0 | Citations (PDF) |
| 541 | Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351 | 5.0 | 2 | Citations (PDF) |
| 542 | Outpatient Versus Inpatient Azacitidine Plus Venetoclax Regimen in Elderly Acute Myeloid Leukemia: A Multicenter Retrospective Analysis | 1.8 | 0 | Citations (PDF) |
| 543 | Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real‐life Italian multicenter study | 4.0 | 0 | Citations (PDF) |
| 544 | Molecular characterization of pediatric mastocytosis revealed different somatic mutations with uncertain prognostic value | 3.6 | 0 | Citations (PDF) |
| 545 | Very long‐term outcomes of chronic‐phase chronic myeloid leukaemia patients treated with imatinib: A 25‐year real‐world cohort study | 2.7 | 0 | Citations (PDF) |
| 546 | Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes/neoplasms treated with decitabine: a systematic literature review | 1.5 | 0 | Citations (PDF) |
| 547 | Frontline Nilotinib Versus Dasatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Propensity Score Analysis Based on Agenzia Italiana del Farmaco Monitoring Registries | 1.0 | 0 | Citations (PDF) |
| 548 | Describing the use of ruxolitinib for the treatment of myelofibrosis: a plain language summary of the ROMEI early study results | 2.3 | 0 | Citations (PDF) |
| 549 | Four Decades of Molecular Innovation in Chronic Myeloid Leukemia: From Antisense Targeting to Treatment-Free Remission | 3.8 | 0 | Citations (PDF) |
